OncoMatch/Clinical Trials/NCT05024214
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
Is NCT05024214 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Lenvatinib + Envafolimab and Sunitinib for solid tumors.
Treatment: Lenvatinib + Envafolimab · Sunitinib — This is an open-label, multi-center study of Phase Ib/II study to assess the efficacy and safety of Envafolimab combinded with Lenvatinib in the treatment of subjects with advanced solid tumors. The primary hypothesis of this study is that subjects will have a better objective response rate (ORR) when treated with Envafolimab plus Lenvatinib than SOC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Renal Cell Carcinoma
Hepatocellular Carcinoma
Disease stage
Required: Stage III, IV
Metastatic disease required
Locally advanced or metastatic solid tumors; Unresectable locally advanced or metastatic or recurrent RCC; At least one measurable lesion per RECIST 1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: PD-(L)1 inhibitor
resistance to previous treatment with PD-(L)1 inhibitor
Cannot have received: Lenvatinib (Lenvatinib)
Subjects who were previously treated with Lenvatinib or who participated in a clinical trial of a generic version of Lenvatinib
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify